Risk Factors for Cardiac Dysfunction in Dialysis Patients: Implications for Patient Care
1997; Wiley; Volume: 10; Issue: 3 Linguagem: Inglês
10.1111/j.1525-139x.1997.tb00471.x
ISSN1525-139X
AutoresPatrick S. Parfrey, Robert N. Foley,
Tópico(s)Heart Failure Treatment and Management
ResumoSeminars in DialysisVolume 10, Issue 3 p. 137-141 Risk Factors for Cardiac Dysfunction in Dialysis Patients: Implications for Patient Care Patrick S. Parfrey, Patrick S. Parfrey Department of Medicine, Division of Nephrology, Memorial University of Newfoundland, The Health Sciences Center, St. John's, Newfoundland, CanadaSearch for more papers by this authorRobert N. Foley, Robert N. Foley Department of Medicine, Division of Nephrology, Memorial University of Newfoundland, The Health Sciences Center, St. John's, Newfoundland, CanadaSearch for more papers by this author Patrick S. Parfrey, Patrick S. Parfrey Department of Medicine, Division of Nephrology, Memorial University of Newfoundland, The Health Sciences Center, St. John's, Newfoundland, CanadaSearch for more papers by this authorRobert N. Foley, Robert N. Foley Department of Medicine, Division of Nephrology, Memorial University of Newfoundland, The Health Sciences Center, St. John's, Newfoundland, CanadaSearch for more papers by this author First published: 28 June 2008 https://doi.org/10.1111/j.1525-139X.1997.tb00471.xCitations: 3 Patrick S. Parfrey MD Division of Nephrology, The Health Sciences Center, St. John's, Newfoundland, Canada AIB 3V6 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Churchill DN, Taylor DW, Cook RJ, La Plante P, Barre P, Cartier P, Fay W, Goldstein M, Jindal K, Mandin H, McKenzie JK, Muirhead N, Parfrey PS, Posen GA, Slaughter D, Ulan RA, Werb R:Canadian Hemodialysis Morbidity Study.Am J Kidney Dis 10: 214 234, 1992 2 US Renal Data System: USRDA 1991 Annual Report.Bethesda, The National Institute of Diabetes and Digestive and Kidney Diseases,1991 3 London G & Parfrey PS: Cardiac disease in chronic uremia: Pathogenesis. Adv Renal Repl Ther,1997 (in press) 4 Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE:The outcome and risk factors for left ventricular disorders in chronic uremia.Nephrol Dial Transpl 10: 1277 1285, 1996 5 Harnett JD, Foley RN, Kent GM,et al.:Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors.Kidney Int 10: 884 890, 1995 6 Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE:Outcome and risk factors of ischemic heart disease in chronic uremia.Kidney Int 10: 1428 1434, 1996 7 Foley RN, Parfrey PS, Harnett JD,et al.:Clinical and echocardiographic disease in patients starting end-stage renal disease therapy.Kidney Int 10: 186 192, 1995 8 Rostand RG, Kirk KA, Rutsky EA:Dialysis ischemic heart disease: Insights from coronary angiography.Kidney Int 10: 653 659, 1984 9 Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE:Impact of hypertension on cardiomyopathy, morbidity and mortality in end stage renal disease.Kidney Int 10: 1379 1385, 1996 10 Raine AEG:Acquired aortic stenosis in dialysis patients.Nephron 10: 159 168, 1994 11 London GM, Guerin AP, Marchais SJ,et al.: Cardiac and arterial interactions in end-stage renal disease. Kidney Int1996 (in press) 12 Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE:The impact of anemia on cardiomyopathy, morbidity and mortality in end stage renal disease.Am J Kid Dis 10: 53 61, 1996 13 Chaignon M, Chen WT, Tarazi RC,et al.:Effect of hemodialysis on blood volume distribution and cardiac output.Hypertension 10: 327 332, 1981 14 London GM, Marchais SJ, Guerin AP,et al.: Cardiovascular function in hemodialysis patients, in Advances in Nephrology( 10), edited by Grunfeld JP,Bach JF,Funck-Brentano JL,Maxwell, MH.St Louis, Mosby Year Book,1991 15 London GM, Marchais SJ, Guerin AP,et al.:Cardiac hypertrophy and arterial alterations in end-stage renal disease: Hemodynamic factors.Kidney Int 103: S42 S49, 1993 16 Parfrey PS, Harnett JD, Foley RN, Kent GM, Murray DC, Barre PE, Guttmann RD:Impact of renal transplantation on uremic cardiomyopathy.Transplantation 10: 908 914, 1995 17 Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE:Hypoalbuminemia, cardiac morbidity and mortality in end-stage renal disease.J Am Soc Nephrol 10: 728 736, 1996 18 Foley RN, Parfrey PS, Harnett JD, Kent GM, O'Dea R, Murray DC, Barre PE: Mode of dialysis therapy and mortality in endstage renal disease. Kidney Int1997 (in review process) 19 Bogin E, Massry SG, Harary I:Effect of parathyroid hormone on rat heart cells.J Clin Invest 10: 1215 1227, 1981 20 Amann K, Wiest G, Klaus G,et al.:The role of parathyroid hormone in the genesis of interstitial cell activation in uraemia.J Am Soc Nephrol 10: 1814 1819, 1994 21 London GM, Fabiani F, Marchais SJ,et al.:Uremic cardiomyopathy: An inadequate left ventricular hypertrophy.Kidney Int 10: 973 980, 1987 22 Massry SG & Smorgorzewski M:Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia.Semin Nephrol 10: 219 231, 1994 23 Foley RN, Parfrey PS, Harnett JD, Kent GM, Hu L, O'Dea R, Murray DC, Barre PE:Hypocalcemia, morbidity and mortality in end stage renal disease.Am J Nephrol 10: 386 393, 1996 24 Rostand SG, Kirk KA, Rutsky EA:The epidemiology of coronary artery disease in patients on maintenance hemodialysis: Implications for management, inThe Heart in End Stage Renal Disease edited by Wizemann V,Kramer W,Shutterle G.Contrib Nephrol 10: 34 41, 1986 25 Tschope W, Koch M, Thomas B, Ritz E,German Study Group Diabetes and Uremia: Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study.Nephron 10: 354 358, 1993 26 D'Elia JA, Wwinrauch LA, Gleason RE, deSilva RA, Nestro R:Preliminary screening of the relationship of serum lipids to screening of chronic dialysis patients.Renal Failure 10: 203 209, 1993 27 Cressman MD, Abbound D, O'Neil J, Hoff HF:Lp(a) and premature mortality during hemodialysis treatment.Chem Phys Lipids 10: 419 427, 1994 28 Chauveau P, Chadefaux B, Coude M, Aupetit J, Hannedouche T, Kamoun P, Junger S:Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients.Kidney Int 10 3: S72 S77, 1993 29 Bostom AG, Shemin D, Lapane KL, Sutherland P, Nadeau MR, Wilson PWF, Yoburn D, Bausserman L, Tofler G, Jacques PF, Selhub J, Rosenberg IH: Hyperhomocysteinemia, hyprefibrinogenemia, and lipoprotein(a) excess in maintenance dialysis patients: A matched case control study. Atherosclerosis1996 (in press) 30 Bostom AG, Shemin D, Lapane KL, Nadeau MR, Sutherland P, Chan J, Rozen R, Yoburn D, Jacques PF, Selhub J, Rosenberg IH:Folate status is the major determinant of fasting total plasma homocystein levels in maintenance dialysis patients.Atherosclerosis 10: 193 202, 1996 31 Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg IH:High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients.Kidney Int 10: 147 152, 1996 32 Witzum JL & Steinberg D. Role of oxidized low density lipoprotein in atherogenesis.J Clin Invest 10: 1785 1792, 1991 33 Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA:Plasma levels of IL1-Beta, TNF-alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients.Kidney Int 10: 890 896, 1994 34 Cohen JD, Viljoen M, Clifford D, DeOliveria AA, Veriava Y, Milne FJ:Plasma vitamin E levels in a chronically hemolyzing group of dialysis patients.Clin Nephrol 10: 42 47, 1986 35 Culleton BF, Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE:Cardiac disease in diabetic patients with ESRD (abstract).JASN 10: 1443, 1996 36 U.S. Renal Data System 1992 Annual Report. IV: Comorbidconditions andcorrelations with mortality risk among 3,399 incident hemodialysis patients. Am J Kidney Dis3: 32 38, 1992 37 McMillan MA, Briggs JD, Junor BJ:Outcome of renal replacement therapy in patients with diabetes mellitus.BMJ 10: 540 544, 1990 Citing Literature Volume10, Issue3May 1997Pages 137-141 ReferencesRelatedInformation
Referência(s)